Ad hoc announcement pursuant to Art. 53 LR
Statement of SKAN Group AG on an investigation by the Office of the Attorney General of Switzerland
Allschwil, 25 May 2023 – SKAN Group AG confirms that the Office of the Attorney General of Switzerland has initiated an investigation. The investigation relates to transactions with shares of BV Holding AG from the time before the IPO.
As soon as further findings result from the investigation, SKAN Group will inform again.
Contacts:
Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13
Financial calendar:
22 August 2023
26 March 2024
7 May 2024 |
Publication of the half-year results 2023
Publication annual results 2023
Annual General Meeting 2024 |
SKAN – together always one step ahead
SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organization make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organizations) and research laboratories worldwide. Founded in 1968, SKAN today employs over 1170 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan and the USA.
.